Objective: To examine the comorbidity of Axis I and II disorders within a community-based sample of adults with schizophrenia.
S chizophrenia is often a chronic, severely debilitating disorder with a poorer overall outcome compared with any other major mental illness. 1 Suicide rates among people diagnosed with schizophrenia are abnormally high. [1] [2] [3] In addition, these people are more likely to fall into the lowest SES group, 1 have a significantly lower employment rate than people without schizophrenia, 2, 4 and are more likely to live in poverty than people with MDD, alcohol abuse, or alcohol dependence. 5 Numerous studies have demonstrated high comorbidity with DSM-IV mood disorders, [6] [7] [8] [9] SUDs, 3, 7, [10] [11] [12] PDs, 7, 13, 14 and anxiety disorders. 2, 3, 7, [15] [16] [17] [18] Even after adjusting for anxiety related to delusions or hallucinations, the relation between anxiety disorders and schizophrenia remains strong. 19 Mood disorders are especially prevalent in patients with schizophrenia. One study of DSM-IV-diagnosed patients with schizophrenia found that nearly one-half (46%) met criteria for MDD at one or both follow-ups conducted 4.5 and 7.5 years after hospital discharge. 20 SUDs appear to show the highest comorbidity with schizophrenia. The Epidemiologic Catchment Area Study included 20 291 people from within the United States and found that 47% of people with a diagnosis of schizophrenia had a co-occurring substance abuse or dependence disorder. 21 Rates of comorbid SUDs are especially high in men 6, [22] [23] [24] and those diagnosed with panic attacks. 25 The substances shown to be most frequently abused by people diagnosed with schizophrenia are cannabis 11, 23, [26] [27] [28] [29] and alcohol. 7, [30] [31] [32] In contrast to the DSM Axis I disorders (major depression, dysthymia, mania, panic disorder with or without agoraphobia, agoraphobia without panic, social phobia, specific phobia, generalized anxiety disorder, alcohol dependence, alcohol abuse, drug dependence, and drug abuse), Axis II PDs (paranoid, schizoid, antisocial, histrionic, avoidant, dependent, and obsessive-compulsive) have received relatively little attention among patients with schizophrenia. The relation between several Axis I clinical disorders and Axis II PD were recently examined in the NESARC; however, these studies did not include people with a diagnosis of schizophrenia. 33, 34 APD is the most well researched comorbid PD among people with schizophrenia and has been linked to an increased rate of alcohol and drug abuse and (or) dependence as well as criminal offences. 13, 35 Although less research has been conducted examining the relation between avoidant and dependent PD with schizophrenia, researchers have demonstrated strong comorbid associations with avoidant and dependent traits. 36 Family studies also support a relation between schizophrenia and PD. Specifically, nonpsychotic biological family members of schizophrenia probands have been shown to be at increased risk for schizotypal PD, paranoid PD, 37 and avoidant PD. 14 More research is needed to elucidate the relation between the remaining DSM-IV PDs and schizophrenia.
Previous literature has suffered several shortcomings. First, most studies have focused on institutionalized or treatmentseeking samples. These samples may be biased in that only the most severely disabled people are likely to be institutionalized. As well, people that seek treatment are likely to have higher levels of comorbidity and increased severity and disability related to their disorder. Additionally, despite population-based research 21 that has been done on the comorbidity between people that communicate a diagnosis of schizophrenia and some of the DSM Axis I disorders, relatively little has been done to examine the comorbidity with Axis II PD.
Our study improves on previous studies in several ways. First, the current study uses the NESARC, a large populationbased sample from the United States. The advantage of epidemiologic studies such as our study is that the bias associated with a treatment-seeking sample is reduced. Second, both Axis I and II PDs were examined in detail. Finally, the large, nationally representative dataset used in our study provides a substantially larger subset of patients with SPIE than found in the existing literature. The main 2 objectives of our study were: to determine the prevalence of Axis I and Axis II disorders among people with SPIE; and, to investigate which Axis II PDs showed the highest level of comorbidity with SPIE. 
Methods

Sample
Psychiatric Diagnosis
The diagnosis of lifetime SPIE (n = 386) was given to any person who answered yes to the question, "Did a doctor or other health professional ever diagnose you with schizophrenia or psychotic illness or episode?" This method was evaluated in a recent study by Supina et al 39 using a very similar self-report question to the one used in our study. The results echoed accepted prevalence rates of schizophrenia in the North American population, which supports the methodology used in this study. 39 Other psychiatric disorders included in the analyses were assessed using the AUDADIS, a DSM-IV-based interview instrument that was used to diagnose mood disorders (MDD, mania, and dysthymia), PDs (paranoid, histrionic, schizoid, antisocial, avoidant, dependent, and obsessive-compulsive), anxiety disorders (panic with or without agoraphobia, agoraphobia without panic, generalized anxiety disorder, and social and specific phobias), and SUDs (cannabis, solvents, amphetamines, opioids, sedatives, tranquilizers, cocaine, hallucinogens, heroin, and alcohol). The AUDADIS-IV was reviewed extensively in 2003 and was found to be highly reliable in diagnosing alcohol and psychiatric disorders in the general population. Additional information on this study and the reliability and validity of the AUDADIS can be found elsewhere. 40, 41 Some of the PDs assessed in our study share features similar to symptoms that may be experienced by a person with a diagnosis of SPIE (for example, paranoid PD). Although these disorders can be diagnosed separately from a comorbid diagnosis of SPIE, it is possible that some people with a diagnosis of SPIE may endorse the diagnostic criteria for these PDs based on symptoms they experienced as a result of their SPIE. To diminish the likelihood of misclassifying people, they were reminded on 20 occasions throughout this section of the interview to exclude reporting incidents in which they were depressed, anxious, manic, drinking heavily, experiencing symptoms of withdrawal from medication or drugs, using medication or drugs, or physically ill.
Measures
The Medical Outcomes Study SF-12 questionnaire was used to evaluate the impact of comorbid disorders on quality of life. This 12-item survey measures both physical and mental quality of life within the domains of physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health.
Data Analysis
All statistical analyses were conducted in SUDAAN 42 using the appropriate weights provided by the NESARC to more accurately represent the US population. Estimates of variance were conducted using the Taylor Series Linearization procedure to correct for the complex statistical sampling procedures employed by the NESARC. All diagnoses were made in accordance with DSM-IV diagnostic criteria and were calculated hierarchy-free for both past-year and lifetime prevalence. Chi-square analyses were calculated for all sociodemographic variables (age, sex, education, marital status, and household income) to identify significant differences between people with or without a diagnosis of SPIE in these domains.
Individual disorders were first examined separately then later grouped into 1 of 5 clusters for subsequent analysis: any lifetime mood disorder, anxiety disorder, PD, substance dependence, and SUD. Logistic regressions were performed with each Axis I and II disorder after adjusting for sociodemographics. Analogous statistical procedures were conducted for each individual drug after combining drug abuse and drug dependence. Additional logistic regressions were computed for each of the Axis I and II diagnostic clusters after adjusting for sociodemographics and every other diagnostic cluster simultaneously.
Three separate groups of analyses were performed on the SUDs. The first analysis combined alcohol abuse with drug abuse, and alcohol dependence with drug dependence to form the substance abuse and substance dependence variables. Additionally, alcohol abuse, alcohol dependence, drug abuse, and drug dependence were considered separately to allow for a more focused analysis. Finally, drug abuse and dependence were combined to form a third variable: drug abuse and (or) dependence that was used to examine each drug separately.
Cross-tabulations were calculated comparing each variable previously mentioned against our lifetime SPIE variable to determine both the prevalence and the distribution of Axis I, Axis II, and SUDs among participants with or without a diagnosis of SPIE.
To determine the impact of comorbid disorders on the quality of life of a person diagnosed with SPIE, linear regressions were calculated using the mental and physical health components of the SF-12 Quality of Life scale. People diagnosed with SPIE were dichotomized into 2 groups: those with a comorbid Axis I or II disorder and those without. Past-year diagnoses were used for mood, anxiety, drug and alcohol abuse, and (or) dependence disorders, while lifetime diagnoses were used for PDs. Mean SF-12 scores were calculated for each group and differences in mean SF-12 mental and physical health scores between the 2 groups were evaluated for statistical significance.
Because of the possibility that participants with a diagnosis of mania might have been misdiagnosed with SPIE (rather than a diagnosis of bipolar or schizoaffective disorder), all of the data were reanalyzed in the same manner after removal of all people who had endorsed a diagnosis of mania. In addition, the use of lifetime mental disorder diagnoses can be limited in that some people may not have yet passed through the risk period for developing a mental disorder and may be less likely to demonstrate comorbidity than an older person. For this reason, analysis of each individual mood, anxiety, and SUD was conducted a second time using past-year diagnoses.
Results
Sociodemographics Table 1 presents the sociodemographic correlates of SPIE. An overall chi-square analysis indicated significant differences in the prevalence of SPIE among the 4 age groups, with the majority of people diagnosed with SPIE being from the 30 to 44 years (33.9%) and 45 to 64 years (33.9%) age groups. Differences in prevalence rates between sexes were nonsignificant. Chi-square analyses also indicated significant differences in the level of education, income, and marital status for people with a diagnosis of SPIE and those without. People with SPIE were more likely than those without to drop out of high school at or below grade 12 (23.4%, compared with 15.5%), and less likely to obtain a college education or better (44.5%, compared with 55.2%). They were also more likely to live in poverty, with nearly one-half surviving on a total annual household income of less than $19 999, and less likely to be currently married.
Axis I Disorders
Each of the Axis I mood disorders, anxiety disorders, and SUDs were examined for both past-year and lifetime prevalence. Past-year results closely resembled those obtained using lifetime data. Therefore, for the sake of brevity, only lifetime data are presented (data are available on request). Examined individually, odds ratios for almost all of the Axis I disorders presented in Table 2 were statistically significant (P < 0.001), with significant odds ratios ranging from 3.40 (95% CI 2.46 to 4.69) for lifetime specific phobia, to 14.88 (95% CI 11.26 to 19.66) for lifetime mania. Lifetime alcohol abuse was not significantly more common among people with a diagnosis of SPIE; however, alcohol dependence was far more common in this group with an odds ratio of 4.40 (95% CI 3.28 to 5.91). MDD was the most commonly diagnosed Axis I disorder, with 62.2% of people with SPIE receiving this diagnosis.
As shown in Table 3 , each cluster of Axis I lifetime disorders occurred more frequently in respondents with a diagnosis of SPIE and all produced significant odds ratios (P < 0.001).
Mood disorders were the most commonly co-occurring Axis I disorder cluster with 71% of people diagnosed with SPIE concomitantly diagnosed with a mood disorder. To further elucidate the connection between the Axis I disorders and schizophrenia, our diagnostic clusters were reanalyzed after adjusting for sociodemographics and every other diagnostic cluster, simultaneously. Anxiety disorders and substance dependence no longer remained significantly associated. However, this analysis demonstrated the significant comorbidity between mood, personality, and substance dependence disorders with schizophrenia (P < 0.001).
Drug Use Disorders
Every drug category examined in our study (with the exception of the "other drug" category) produced significant odds ratios (P < 0.001) after adjusting for sociodemographics. Cannabis was the drug used most often by people diagnosed with SPIE, with 28.6% endorsing lifetime abuse or dependence. Every drug examined in our study was used most often by people with SPIE, compared with our comparison group, with odds ratios as high as 9.57 (95% CI 5.13 to 17.85) for tranquilizers.
Axis II Disorders
The Axis II PDs were first examined individually and then as a cluster. Examined individually after adjusting for sociodemographics ( Following the removal of all participants diagnosed with mania, identical analyses were conducted again. The pattern of results was overall very similar to the findings discussed above. Small reductions in odds ratios were observed on almost all variables, but this did not alter their level of significance. Additional data are available on request.
Quality of Life
As shown in Figure 1 , comorbid disorders have a significant impact on the quality of life of people diagnosed with SPIE in both mental and physical domains. Although the detrimental impact of having a comorbid disorder was greatest for the mental health component of the SF-12 (P < 0.001), significant differences were also found between people with and without a comorbid disorder for the physical health component of the SF-12 (P < 0.05).
Discussion
To our knowledge, our study used the largest nationally representative, community-based sample of people with SPIE in the literature. SUDs, people with a diagnosis of SPIE were 3.28 times more likely to suffer from at least one PD than our comparison group. While many of these PDs have not been previously studied in psychiatric, epidemiologic investigations of schizophrenia and related conditions, APD has received much attention and was present in more than one-fifth of our SPIE sample.
Avoidant and paranoid PDs were the most common Axis II disorders in our community sample. Paranoid PD has been accepted as one of several schizophrenia spectrum disorders along with schizoaffective disorder, atypical psychosis, and schizotypal PD. Until recently, avoidant PD has generally not been associated with schizophrenia. In 2007, Fogelson et al 14 conducted a groundbreaking study examining the rates of avoidant PD in probands with schizophrenia, their first-degree relatives, and community control subjects. They found that first-degree relatives were far more likely than community control subjects to be diagnosed with avoidant PD even after controlling for schizotypal and paranoid PDs. It is possible that people with a history of schizophrenia use avoidant behaviour to deal with the rejection, shame, and negative stereotypes that frequently accompany severe mental illness to such a degree that it becomes pathological. Avoidant behaviour may also reflect negative symptoms of schizophrenia or an attempt to deal with positive symptoms through control of external stimuli. These factors may help explain the high rates of comorbid avoidant PD found in our sample. Exploring the characteristics of this relation between schizophrenia and avoidant PD could be a useful direction for future research. Dependent PD was also diagnosed substantially more often among participants with SPIE, compared with those without. This extremely high rate of comorbidity is likely due to the significant impairment suffered by people with schizophrenia and their resulting reliance on caregivers.
Regarding Axis I clinical disorders, numerous studies have demonstrated that rates of substance abuse and dependence are higher in schizophrenia. Our study confirms these findings with more than one-third of our sample diagnosed with DSM-IV substance abuse. Even more striking was that almost one-half were found to be substance-dependent. Similar to results of previous studies, 7,30-32 we found that the most commonly misused substance was alcohol, with 54.8% of our SPIE sample diagnosed with alcohol abuse or dependence.
Drug abuse and dependence rates were similarly high but comparable to the alcohol abuse and (or) dependence and drug abuse and (or) dependence rates observed by Bland et al. 7 The most commonly abused drug by people who communicated a diagnosis of SPIE as well by our comparison group was cannabis (28.6%), although the rate of cannabis use by those with a diagnosis of SPIE was somewhat lower than the 31% to 41.8% found in previous studies. 43 Numerous studies support our finding that cannabis is the preferred drug for those diagnosed with schizophrenia 11, 23, [26] [27] [28] [29] ; however, the reasons have not yet been elucidated.
Continued research into the relation between schizophrenia and SUDs is extremely important given that previous studies have demonstrated that patients with a comorbid SUD show increased rates of treatment noncompliance, 30, 44 violence and suicide, 28, 29, 44 exacerbation or earlier onset of symptoms, 23, 27, 29, 30, 43 and lower cognitive functioning. 31, 45 An investigation into mood and anxiety disorders among patients with schizophrenia revealed similarly high rates of comorbidity. A twin study by Lyons et al 9 found that among twins discordant for schizophrenia, the twin diagnosed with schizophrenia was significantly more likely to be diagnosed with a mood or anxiety disorder than their healthy twin. In particular, social phobia was found to be very common in our SPIE sample, co-occurring in 22.3%. Mood disorders were also highly prevalent among people in our sample with a diagnosis of SPIE, with 62.2% diagnosed with MDD. MDD in patients with schizophrenia is very common and is linked to multiple negative outcomes such as decreased life satisfaction, an increase in physical limitations, smaller social networks, and an increased risk of suicide. 8, 20 Continuing research into depression in people with schizophrenia is highly important because of the high rates of suicide found in this population.
Although numerous studies have investigated the various comorbidities that accompany schizophrenia, few have demonstrated any association between multiple psychiatric diagnoses and decreased mental or physical quality of life within this group. The results of our study indicate that people with a diagnosis of SPIE who were concomitantly diagnosed with an Axis I or II psychiatric disorder had significantly lower quality of life scores in both mental and physical domains. Thus providing treatment for these comorbid disorders whenever possible may lead to better mental and physical outcomes.
A limitation of our study is that schizophrenia was not diagnosed in the same manner as the Axis I and II disorders. Although a diagnosis of schizophrenia by a clinician would likely be more accurate compared with the self-report method used in our study, this was not possible using the current dataset. However, this method has been used in several peer-reviewed journals and has been viewed as a valid assessment technique. 39, 46 This self-report method of diagnosis is further supported by a recent comprehensive review of the schizophrenia literature published in the Lancet. 47 This article examined the epidemiology, characteristics, and course of schizophrenia in 161 recent journal articles and book chapters and found very similar lifetime rates of schizophrenia (1.0%) to those found in our study (0.90%). In addition, similar age and sex distributions were observed, which provides additional support for the validity of this assessment method.
Other limitations of our study include the cross-sectional nature of the data, the use of professional interviewers rather than trained clinicians, and the inclusion of only community dwelling noninstitutionalized respondents. Another limitation is that schizophrenia and depression were assessed but not schizoaffective disorder. Schizoaffective disorder would have been difficult to assess using nonclinician interviewers working with a structured interview and could have been misdiagnosed as schizophrenia, bipolar disorder, or MDD. In addition, the high rates of avoidant and dependent PDs found in our sample may be a function of the similarity between the criteria for the diagnosis of these PDs and the negative symptoms of schizophrenia, which may be partially explained by the reliance on professional interviewers rather than experienced clinical interviewers. Finally, the current dataset does not allow for a temporal examination of the relation between schizophrenia and PDs, thus inferences concerning directionality cannot be made.
The results of our study are of clinical importance for several reasons. First, the data provides additional support for the link between substance abuse, mood, and anxiety disorders with schizophrenia. Second, our data provide evidence that PDs may play a far greater role in schizophrenia than otherwise thought. Even under the most stringent conditions, PDs showed high rates of comorbidity with SPIE in our sample. In addition, the individual analyses of PDs allowed for a more fine-grained investigation and demonstrated the significant link between avoidant and dependent PDs with schizophrenia. Finally, the significant contributions made by comorbid disorders in determining quality of life for people with schizophrenia suggests that treating these comorbidities may lead to better mental and physical functioning. Additional research is needed to confirm this hypothesis.
Conclusions
A recent study conducted using self-report data from the Canadian Community Health Survey: Mental Health and Well-Being found identical lifetime rates of schizophrenia and (or) psychotic illness to those observed in the current study across all Canadian provinces. 39 However, currently there are no available datasets that would allow an extensive investigation into the comorbidity of schizophrenia and both Axis I and II clinical disorders in Canadian communities. Until such data becomes available, Canadian clinicians serve to benefit from large, population-based datasets such as the NESARC when evaluating patients with schizophrenia who may suffer from a comorbid PD.
Based on the substantial comorbidity between schizophrenia and the Axis I and II disorders investigated, clinicians should be aware that these potentially treatable concurrent diagnoses are very common in schizophrenia and treatment of these comorbidities may lead to better clinical outcomes. Clinicians should consider screening for mood, anxiety, substance, and PDs when treating a patient with schizophrenia to increase quality of life for the patient and help prevent complications in treatment. 
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Résumé : La comorbidité des troubles mentaux de l'axe I et II avec la schizophrénie et les troubles psychotiques : les résultats de l'enquête épidémiologique nationale sur l'alcool et les troubles reliés
Objectif : Examiner la comorbidité des troubles de l'axe I et II auprès d'un échantillon communautaire d'adultes souffrant de schizophrénie.
Méthodes : L'étude a été menée à l'aide de données de l'enquête épidémiologique nationale sur l'alcool et les troubles connexes (NESARC). Un diagnostic de schizophrénie était basé sur l'autodéclaration des répondants qui avaient reçu un diagnostic de schizophrénie ou de maladie ou épisode psychotique (SMEP). Les troubles de l'axe I et les troubles de la personnalité (TP) de l'axe II ont été évalués à l'aide du plan d'entrevue pour les troubles associés à la consommation d'alcool et aux problèmes connexes. La qualité de vie mentale et physique a été évaluée au moyen du questionnaire abrégé en 12 items de l'étude des résultats médicaux.
Résultats : La prévalence de SMEP était de 0,9 %. Nous avons utilisé la régression logistique multiple pour examiner l'association entre la présence et l'absence de SMEP dans les troubles mentaux de l'axe I et II. Tous les troubles mentaux de l'axe I et II examinés étaient significativement associés à un diagnostic de SMEP après ajustement selon l'âge, le sexe, le niveau d'instruction, l'état matrimonial, et le revenu du ménage.
Conclusions :
Les cliniciens devraient être conscients des modèles et de l'étendue des comorbidités psychiatriques qui peuvent exister dans la schizophrénie. Les mécanismes possibles de ces associations sont discutés.
